ZEGFROVY

Biogen is a leading global biotechnology company dedicated to the discovery and development of innovative therapies for people living with serious neurological and neurodegenerative diseases. The company maintains a robust portfolio of treatments for multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. In 2023, Biogen significantly expanded its rare disease franchise through the acquisition of Reata Pharmaceuticals, which added Skyclarys (omaveloxolone) to its commercial lineup as the first FDA-approved treatment for Friedreich's ataxia. Biogen continues to leverage its expertise in neuroscience to advance a diverse pipeline targeting conditions such as Parkinson's disease, lupus, and various rare genetic disorders.